Ingenuity Systems and Affymetrix (Santa Clara, California) Partner to Eliminate Microarray Expression Analysis Bottleneck
Published: Apr 08, 2013
REDWOOD CITY, Calif. and SANTA CLARA, Calif., April 8, 2013 /PRNewswire/ -- Ingenuity® Systems, a leading provider of biomedical information and analysis solutions, and Affymetrix®, Inc. (NASDAQ: AFFX) today announced that they will co-promote Ingenuity® iReport with Affymetrix expression microarray products effectively eliminating a bottleneck for researchers working with human, mouse and rat applications by coupling a fast and accurate statistical analysis and biological interpretation workflow with the gold-standard platform for gene expression studies.
Affymetrix expression microarrays are the standard methodology used for many research and discovery applications and when combined with Ingenuity iReport, an interactive web-based report that leverages the Ingenuity Knowledge Base of biological and chemical findings from the peer reviewed literature and databases, deliver researchers a 'sample to insight' continuous workflow allowing for rapid, confident interpretation of results without the need for bioinformatics experience or support.
"We are excited to partner with Ingenuity Systems to provide our array users with access to the intuitive biological and statistical analysis platform offered by iReport," said Kevin Cannon, Ph.D., SVP - Expression Business Unit at Affymetrix. "Bundling together our robust expression microarrays with the iReport platform will provide Affymetrix' customers with a simple and accurate tool to convert data into biologically relevant results."
"By leveraging Ingenuity iReport with Affymetrix gene expression arrays for our study on a mouse model of Familial Hypertrophic Cardiomyopathy, we accelerated our data interpretation several-fold compared to using other analysis tools. Their rapid and effectively-blind analysis provided an unbiased validation of our data. Additionally, iReport allowed us to identify and explore genes of interest found with Affymetrix gene chips, yet not identified by other analysis tools," said Adrian Grimes, Ph.D., from the Department of Pediatrics at the University of Wisconsin.
About Ingenuity® Systems
Ingenuity® Systems is a leading provider of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems in life science research and molecular diagnostics. Today, Ingenuity's solutions are used by tens of thousands of researchers and clinicians at hundreds of leading pharmaceutical, biotechnology, academic, diagnostic and clinical institutions worldwide.
Affymetrix' technologies are used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.
PLEASE NOTE: Affymetrix® and the Affymetrix logo are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.
Products mentioned in this release are for research use only. Not for diagnostic procedures.
SOURCE Ingenuity Systems